Pharma companies directory 2026

    Pharmaceutical Companies in Kazakhstan

    Kazakhstan’s medicine market reached about USD 2.53 billion in 2024 on Proxima Research figures, split between a USD 1.42 billion retail pharmacy trade and a USD 1.11 billion hospital channel that a single state wholesaler, SK-Pharmacy, is legally empowered to feed.

    Registration now runs on two tracks: a national file and, increasingly, the Eurasian Economic Union common-market procedure. The Ministry of Health sets policy; the National Center for Expertise of Medicines reviews dossiers; SK-Pharmacy, the unified distributor created in 2009 and now owned by the ministry, buys for the guaranteed basic-care package and for compulsory social health insurance (OSMS). The Social Health Insurance Fund reported 15.9 million people insured under OSMS in 2024 — coverage rates quoted by officials have ranged from the low eighties to the low nineties depending on the year and the definition — and that insured demand is what makes a SK-Pharmacy award valuable. Localisation is the other political fact: the government has said it wants domestic plants to supply half of public-sector medicines, and long-term contracts with Chimpharm (Santo), Nobel AFF, Abdi Ibrahim Global Pharm and Kelun-Kazpharm are the instrument. Pfizer, Sanofi, Novartis, Roche and Bayer keep Almaty affiliates and have signed, or been invited to sign, contract-manufacturing memoranda. BioNixus uses the companies below when a client needs to know who can actually put a pack on an Almaty or Astana hospital shelf.

    Updated September 2026 · Ministry of Health of the Republic of Kazakhstan — Committee for Medical and Pharmaceutical Control / National Center for Expertise of Medicines as of September 2026 · 18 named accounts

    Request a proposal for KazakhstanBrowse the 18 companies

    USD 2.53bn

    Kazakh pharmaceutical sales in 2024 (Proxima Research, +14.5% on 2023)

    USD 1.11bn

    Hospital-channel value in 2024, versus USD 1.42bn retail (Proxima)

    15.9m

    People recorded as insured under OSMS in 2024 (Social Health Insurance Fund)

    50%

    Stated government target for the domestic share of public-sector medicines

    Named accounts

    Top pharmaceutical companies in Kazakhstan

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Ministry of Health of the Republic of Kazakhstan — Committee for Medical and Pharmaceutical Control / National Center for Expertise of Medicines (as of 2026-09-04).
    #CompanyHQ
    01Ministry of Health of the Republic of KazakhstanAstana
    02National Center for Expertise of MedicinesAstana
    03SK-PharmacyAstana
    04Chimpharm (Santo)Shymkent
    05Nobel Almaty Pharmaceutical Factory (Nobel AFF)Almaty
    06Abdi Ibrahim Global PharmAlmaty
    07Kelun-KazpharmAlmaty Region
    08RomatPavlodar
    09Kyzyl MayAlmaty
    10VIVA PharmAlmaty
    11Pfizer KazakhstanAlmaty
    12Sanofi KazakhstanAlmaty
    13Novartis KazakhstanAlmaty
    14Roche KazakhstanAlmaty
    15Bayer KazakhstanAlmaty
    16STADA (Nizhpharm)Almaty
    17Gedeon Richter KazakhstanAlmaty
    18Social Health Insurance Fund (OSMS)Astana

    Primary research

    These are the pharmaceutical companies accounts we study in Kazakhstan

    Need account-level or SKU-level data for a brand in Kazakhstan? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Kazakhstan?

    Primary research, market access & HEOR. Proposals within 48 hours.

    BioNixus research services

    How the market is structured

    How SK-Pharmacy, EAEU registration and OSMS reimbursement organise supply

    A product needs an expert review from the National Center for Expertise of Medicines and a registration decision from the health ministry’s control committee. Sponsors can file nationally or through the EAEU procedure, which is meant to open the same dossier to Russia, Belarus, Armenia and Kyrgyzstan — useful in theory, still uneven in clock and in national follow-up steps. Once registered, the commercial world splits. Retail pharmacies in Almaty, Astana and the oblasts buy from private wholesalers; that is the USD 1.42 billion cash-and-insurance counter trade. Public hospitals and polyclinics do not. They receive product that SK-Pharmacy has bought under the guaranteed package (GOBMP) and under OSMS, through tenders, long-term contracts of up to ten years with domestic manufacturers, and a smaller set of direct or international-organisation purchases. SK-Pharmacy’s own materials describe dozens of long-term contracts with domestic plants covering thousands of medicine and device SKUs, and a rising share of its spend going to those plants. That is why Chimpharm’s Shymkent site (Santo, part of Poland’s Polpharma), Nobel’s Almaty factory, Abdi Ibrahim Global Pharm and Kelun-Kazpharm are not merely manufacturers — they are the localisation vehicles the unified distributor is paid to prefer. Originators that want public volume either win a SK-Pharmacy lot as an import or put a contract-manufacturing agreement on a Kazakh line, as Pfizer and Roche have already started to do. Pricing for reimbursed products is regulated; retail pricing is freer but still watched. For a launch team the sequence is: NCEM and EAEU file, price submission, then a conscious choice between the retail wholesaler path and the SK-Pharmacy path — or both.

    Local

    Kazakh plants in Almaty, Shymkent and Pavlodar — Nobel AFF, Romat, Kyzyl May, VIVA Pharm — that live on SK-Pharmacy long-term contracts and on the retail audit.

    • Nobel Almaty Pharmaceutical Factory (Nobel AFF)
    • Romat
    • Kyzyl May
    • VIVA Pharm

    Multinational

    Almaty affiliates of Pfizer, Sanofi, Novartis, Roche, Bayer and STADA, now being pulled into contract manufacturing if they want public volume.

    • Pfizer Kazakhstan
    • Sanofi Kazakhstan
    • Novartis Kazakhstan
    • Roche Kazakhstan
    • Bayer Kazakhstan
    • STADA (Nizhpharm)

    Regional

    Polpharma’s Santo, Turkey’s Abdi Ibrahim Global Pharm, Kelun-Kazpharm and Gedeon Richter, which treat Kazakhstan as a manufacturing and EAEU platform.

    • Chimpharm (Santo)
    • Abdi Ibrahim Global Pharm
    • Kelun-Kazpharm
    • Gedeon Richter Kazakhstan

    Distributors & importers

    The ministry, NCEM, the OSMS fund and SK-Pharmacy, whose combined registration, insurance and monopoly-wholesale decisions define the public channel.

    • Ministry of Health of the Republic of Kazakhstan
    • National Center for Expertise of Medicines
    • SK-Pharmacy
    • Social Health Insurance Fund (OSMS)

    What is moving

    What is moving the pharmaceutical market in Kazakhstan

    SK-Pharmacy long-term contracts as industrial policy

    Ten-year awards to domestic plants are how the state is trying to lift the local share of public medicines toward 50%. A manufacturer without such a contract is a retail-only story; an originator without a local site is increasingly an import-only story.

    OSMS on top of the guaranteed package

    Fifteen point nine million people were recorded as insured in 2024, and OSMS paid more than KZT 1.1 trillion of care. That insured hospital demand is what makes a unified-distributor lot valuable, even though coverage percentages still move around in official statements.

    EAEU dossiers as a regional option

    A common-market file can, in principle, open Russia and the rest of the union from an Astana or Almaty base. Clocks and national follow-up still differ, so teams treat EAEU as a parallel path rather than as a substitute for a Kazakh registration.

    Originator contract manufacturing on Kazakh lines

    Pfizer’s vaccine memorandum and Roche’s long-term deal with Nobel AFF are the templates. Localisation is no longer only a generics story; specialty firms are being asked to put a Kazakh plant on the supply map if they want SK-Pharmacy volume.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Kazakhstan

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Kazakhstan:
    • SK-Pharmacy award and ten-year-contract reconstructions by molecule, separating domestic-plant lots from imported originator lots, for Almaty and Astana hospital catchments.
    • NCEM versus EAEU dossier-clock interviews with regulatory heads in Almaty and Astana, used to sequence a dual-track registration plan.
    • Retail pharmacy purchase-record checks in Almaty and Astana estimating Santo, Nobel, STADA and originator share in cardiometabolic and anti-infective baskets.
    • Hospital-pharmacist interviews on what the unified distributor delivered last quarter versus what the formulary listed — the gap that decides whether a “win” was real.

    Questions

    Frequently Asked Questions

    Which pharmaceutical companies matter in Kazakhstan?

    On the domestic side, Santo (Chimpharm), Nobel AFF, Abdi Ibrahim Global Pharm, Kelun-Kazpharm, Romat and VIVA Pharm recur in retail audits and in SK-Pharmacy contractor lists. Sanofi, STADA, Pfizer, Roche, Novartis and Bayer are the originator names that appear in both channels. SK-Pharmacy itself is the public-channel gate.

    Can a company sell to public hospitals without SK-Pharmacy?

    In practice, no. The unified distributor is the legal single wholesaler for GOBMP and OSMS hospital supply. Private pharmacies are a separate retail world; public wards are not.

    Is Abdi Ibrahim actually present in Kazakhstan?

    Yes. The Turkish group operates as Abdi Ibrahim Global Pharm on the former Global Pharm industrial base in the Almaty area, and a 2026 government investment agreement covers a broader multi-profile plant.

    What does EAEU registration change?

    It offers a union-level dossier that can support supply into other EAEU states. It does not replace a Kazakh expert review in every case, and it does not replace a SK-Pharmacy award if the target channel is a public hospital.

    How does BioNixus research pharmaceutical companies in Kazakhstan?

    SK-Pharmacy award and long-term-contract files are mapped by molecule; NCEM and EAEU clock interviews sit with regulatory heads in Almaty and Astana; retail pharmacy audits estimate Santo versus STADA versus originator share; hospital pharmacists are asked what the unified distributor actually delivered last quarter.

    Are the firms below sorted by turnover in Kazakhstan?

    Do not read the table as a size order. Entries were chosen because they keep appearing in SK-Pharmacy awards, EAEU dossiers and BioNixus Almaty and Astana interviews, not because one outsold another.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Kazakhstan. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Ministry of Health of the Republic of Kazakhstan — Committee for Medical and Pharmaceutical Control / National Center for Expertise of Medicines, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Kazakhstan, not size.

    • Proxima Research market figures for 2024 as reported by TAdviser (USD 2.53bn; retail / hospital split)
    • SK-Pharmacy public reports on long-term contracts, localisation share and originator memoranda, 2023–2026
    • Social Health Insurance Fund 2024 results: 15.9 million OSMS insured; Ministry of Health statements on the 50% domestic-supply target
    • BioNixus Kazakhstan hospital, retail-pharmacy and registration fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Kazakhstan?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Kazakhstan?

    Primary research, market access & HEOR. Proposals within 48 hours.